[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE341545T1 - Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase - Google Patents

Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase

Info

Publication number
ATE341545T1
ATE341545T1 AT02745602T AT02745602T ATE341545T1 AT E341545 T1 ATE341545 T1 AT E341545T1 AT 02745602 T AT02745602 T AT 02745602T AT 02745602 T AT02745602 T AT 02745602T AT E341545 T1 ATE341545 T1 AT E341545T1
Authority
AT
Austria
Prior art keywords
quinoline derivatives
tyrosine kinase
kinase inhibitors
containment
medicament
Prior art date
Application number
AT02745602T
Other languages
English (en)
Inventor
Laurent Francois And Hennequin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE341545T1 publication Critical patent/ATE341545T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT02745602T 2001-07-16 2002-07-10 Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase ATE341545T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01401895 2001-07-16
EP01403123 2001-12-05

Publications (1)

Publication Number Publication Date
ATE341545T1 true ATE341545T1 (de) 2006-10-15

Family

ID=26077248

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02745602T ATE341545T1 (de) 2001-07-16 2002-07-10 Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase

Country Status (8)

Country Link
US (1) US7501516B2 (de)
EP (1) EP1409481B1 (de)
JP (1) JP4326328B2 (de)
AT (1) ATE341545T1 (de)
DE (1) DE60215178T2 (de)
ES (1) ES2272737T3 (de)
HK (1) HK1063185A1 (de)
WO (1) WO2003008409A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1313727A1 (de) 2000-08-21 2003-05-28 AstraZeneca AB Chinazolin derivate
JP2004511480A (ja) 2000-10-13 2004-04-15 アストラゼネカ　アクチボラグ キナゾリン誘導体
EP1326859A1 (de) 2000-10-13 2003-07-16 AstraZeneca AB Chinazoline derivate mit aktivität gegen tumore
EP1337524A1 (de) 2000-11-02 2003-08-27 AstraZeneca AB Substituierte chinoline als antitumormittel
US7141577B2 (en) 2001-04-19 2006-11-28 Astrazeneca Ab Quinazoline derivatives
WO2003047584A1 (en) * 2001-12-05 2003-06-12 Astrazeneca Ab Quinoline derivatives
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
GB0215823D0 (en) * 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
ATE429230T1 (de) 2002-07-09 2009-05-15 Astrazeneca Ab Chinazoline derivative und ihre anwendung in der krebsbehandlung
GB0225579D0 (en) 2002-11-02 2002-12-11 Astrazeneca Ab Chemical compounds
BR0315756A (pt) 2002-11-04 2005-09-06 Astrazeneca Ab Derivado de quinazolina ou um seu sal farmaceuticamente aceitável, processo para a preparação do mesmo, composição farmacêutica, uso do dito derivado ou de um seu sal farmaceuticamente aceitável, e, método para produzir um efeito anti-invasivo pela detenção e/ou pelo tratamento de doença de tumor sólido em um animal de sangue quente necessitando de tal tratamento
WO2004069249A1 (en) * 2003-02-03 2004-08-19 Astrazeneca Ab 3-cyano-quinoline derivatives as non-receptor tyrosine kinase inhibitors
WO2004069250A1 (en) * 2003-02-03 2004-08-19 Astrazeneca Ab 3-cyano-quinoline derivatives as non-receptor tyrosine kinase inhibitors
GB0318422D0 (en) * 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
JP4936897B2 (ja) * 2003-12-18 2012-05-23 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗増殖剤としてのピリド−およびピリミドピリミジン誘導体
US7842701B2 (en) 2004-02-19 2010-11-30 Takeda Pharmaceutical Company Limited Pyrazoloquinolone derivative and use thereof
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
WO2008006884A2 (en) * 2006-07-13 2008-01-17 Janssen Pharmaceutica N.V. Mtki quinazoline derivatives
US7884114B2 (en) 2007-08-15 2011-02-08 Glaxo Group Limited Compounds
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
EP2581372B1 (de) * 2010-06-09 2017-06-07 Tianjin Hemay Oncology Pharmaceutical Co., Ltd. Cyanochinolinderivate
WO2016016894A1 (en) 2014-07-30 2016-02-04 Yeda Research And Development Co. Ltd. Media for culturing pluripotent stem cells
MX2018004109A (es) 2015-10-05 2018-09-27 Univ Columbia Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
WO2019165003A1 (en) * 2018-02-20 2019-08-29 Dawei Zhang Substituted quinolines useful as kinase inhibitors
WO2020152686A1 (en) 2019-01-23 2020-07-30 Yeda Research And Development Co. Ltd. Culture media for pluripotent stem cells

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
WO1995024190A2 (en) * 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
JP2000510866A (ja) 1996-05-20 2000-08-22 ダーウィン・ディスカバリー・リミテッド Ｔｎｆとｐｄｅ―ｉｖのインヒビターとしてのキノリンスルホンアミド
IL126557A (en) 1996-05-20 2002-09-12 Darwin Discovery Ltd Quinoline (thio) carboxamides inhibiting TNF or PDE-IV and pharmaceutical preparations containing them
DE69733825T2 (de) 1996-09-25 2006-06-08 Astrazeneca Ab Chinolin-derivate die den effekt von wachstumsfaktoren wie vegf vezögern
ATE246184T1 (de) 1996-11-06 2003-08-15 Darwin Discovery Ltd Chinoline und deren therapeutische verwendung
GB9712761D0 (en) 1997-06-17 1997-08-20 Chiroscience Ltd Quinolines and their therapeutic use
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6288082B1 (en) * 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
PL201475B1 (pl) 1998-09-29 2009-04-30 Wyeth Corp Podstawione 3-cyjanochinoliny jako inhibitory białkowych kinaz tyrozynowych
PT1154774E (pt) * 1999-02-10 2005-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de angiogenese
GB9904103D0 (en) 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
GB9910577D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
PT1202746E (pt) 1999-08-12 2007-01-31 Wyeth Corp Composição contendo um nsaid e um inibidor de cinase de efgr para o tratamento de inibição pólipos do cólon e do cancro colo-rectal
EP1294709A2 (de) 2000-01-28 2003-03-26 AstraZeneca AB Chinolinderivate und deren verwendung als aurora 2 kinase inhibitoren
AR035851A1 (es) 2000-03-28 2004-07-21 Wyeth Corp 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
EP1313727A1 (de) 2000-08-21 2003-05-28 AstraZeneca AB Chinazolin derivate
EP1326859A1 (de) 2000-10-13 2003-07-16 AstraZeneca AB Chinazoline derivate mit aktivität gegen tumore
JP2004511480A (ja) 2000-10-13 2004-04-15 アストラゼネカ　アクチボラグ キナゾリン誘導体
EP1332141A1 (de) 2000-10-25 2003-08-06 AstraZeneca AB Chinazolin derivate
EP1337513A1 (de) 2000-11-02 2003-08-27 AstraZeneca AB 4-substituierte chinoline als antitumormittel
EP1337524A1 (de) 2000-11-02 2003-08-27 AstraZeneca AB Substituierte chinoline als antitumormittel
US7141577B2 (en) 2001-04-19 2006-11-28 Astrazeneca Ab Quinazoline derivatives
US6713462B2 (en) 2001-06-21 2004-03-30 Ariad Pharmaceuticals, Inc. Quinolinones and uses thereof
GB0129099D0 (en) 2001-12-05 2002-01-23 Astrazeneca Ab Chemical compounds
WO2003047584A1 (en) 2001-12-05 2003-06-12 Astrazeneca Ab Quinoline derivatives
WO2003048159A1 (en) 2001-12-05 2003-06-12 Astrazeneca Ab Quinoline derivatives
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives

Also Published As

Publication number Publication date
JP4326328B2 (ja) 2009-09-02
JP2004536860A (ja) 2004-12-09
EP1409481A1 (de) 2004-04-21
DE60215178T2 (de) 2007-08-23
US7501516B2 (en) 2009-03-10
ES2272737T3 (es) 2007-05-01
EP1409481B1 (de) 2006-10-04
HK1063185A1 (en) 2004-12-17
DE60215178D1 (de) 2006-11-16
US20050009867A1 (en) 2005-01-13
WO2003008409A1 (en) 2003-01-30

Similar Documents

Publication Publication Date Title
ATE341545T1 (de) Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase
NO20025792D0 (no) Kinazolinderivater for behandling av tumorer
ATE353888T1 (de) Chinazolinderivate
MY129809A (en) Quinazoline derivatives
DE602004011199D1 (de) 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren
NO20061415L (no) Kinazolinderivater
ATE409185T1 (de) Chinazolin derivate
SG154433A1 (en) Phthalazine derivatives as parp inhibitors
TW200608977A (en) Substituted 2-alkyl quinazolinone derivatives as parp inhibitors
SE0301700D0 (sv) Novel compounds
ES2195785A1 (es) Nuevos derivados de piridazin-3(2h)-ona.
UA88012C2 (uk) Похідні хіназоліндіону як інгібітори parp
ATE296826T1 (de) Pyrazolo(1,5)pyridinderivate
IL163090A (en) Nicotinamide derivates, pharmaceutical compositions comprising them and their use for manufacture of medicaments useful as p38 inhibitors
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
IS2855B (is) 4-anilínókínasólínafleiður sem andfjölgunarefni
GB0124933D0 (en) Chemical compounds
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
ATE400570T1 (de) 2,4,6-trisubstituierte pyrimidine als inhibitoren von phosphatidylinosit-(pi-)3-kinase und deren verwendung bei der behandlung von krebs
ATE300541T1 (de) Pyrazolopyridinderivate
MXPA04002042A (es) Compuestos de bencimidazol sustituidos y su uso para el tratamiento del cancer.
ATE287886T1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer
WO2003053960A3 (en) Quinline derivates and their use as mek inhibitors
ATE429230T1 (de) Chinazoline derivative und ihre anwendung in der krebsbehandlung
MY137835A (en) Quinazoline derivatives as src tyrosine kinase inhibitors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties